BiomX (NYSEAMERICAN:PHGE) Stock Price Expected to Rise, HC Wainwright Analyst Says

BiomX (NYSEAMERICAN:PHGE) had its price objective boosted by HC Wainwright from $2.00 to $21.00 in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

BiomX Price Performance

Shares of NYSEAMERICAN:PHGE opened at $0.49 on Tuesday. BiomX has a 52 week low of $0.48 and a 52 week high of $4.99. The company has a market capitalization of $8.96 million, a P/E ratio of -0.15 and a beta of 1.27.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).